RT Journal Article
SR Electronic
T1 Development and clinical application of a rapid and sensitive loop-mediated isothermal amplification test for SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.20.20108530
DO 10.1101/2020.05.20.20108530
A1 Hu, Xuejiao
A1 Deng, Qianyun
A1 Li, Junmin
A1 Chen, Jierong
A1 Wang, Zixia
A1 Zhang, Xiqin
A1 Fang, Zhixin
A1 Li, Haijian
A1 Zhao, Yunhu
A1 Yu, Pan
A1 Li, Wenmin
A1 Wang, Xiaoming
A1 Li, Shan
A1 Zhang, Lei
A1 Hou, Tieying
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.20.20108530.abstract
AB Background The SARS-CoV-2 outbreak urgently requires sensitive and convenient COVID-19 diagnostics for the containment and timely treatment of patients. We aimed to develop and validate a novel reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay to detect SARS-CoV-2 in qualified laboratories and point-of-care settings.Methods Patients with suspected COVID-19 and close contacts were recruited from two hospitals between Jan 26 and April 8, 2020. Respiratory samples were collected and tested using the RT-LAMP assays, and the results were compared with those obtained by RT-qPCR. Samples yielding inconsistent results between these two methods were subjected to next-generation sequencing for confirmation. The RT-LAMP assay was also tested on an asymptomatic COVID-19 carrier and patients with other respiratory viral infections.Results Samples were collected from a cohort of 129 cases (329 nasopharyngeal swabs) and an independent cohort of 76 patients (152 nasopharyngeal swabs and sputum samples). The RT-LAMP assay was validated to be accurate (overall sensitivity and specificity: 88.89% and 99.00%; positive and negative predictive values: 94.74% and 97.78%, respectively) and diagnostically useful (positive and negative likelihood ratios: 88.89 and 0.11, respectively). RT-LAMP showed an increased sensitivity (88.89% vs 81.48%) and high consistency (kappa 0.92) compared with RT-qPCR for SARS-CoV-2 screening while requiring only constant temperature heating and visual inspection. The time required for RT-LAMP was less than 1 h from sample preparation to result. In addition, RT-LAMP was feasible for use with asymptomatic patients and did not cross-react with other respiratory pathogens.Conclusion The developed RT-LAMP assay offers rapid, sensitive and straightforward detection of SARS-CoV-2 infection and could aid the expansion of COVID-19 testing in the public domain and hospitals.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNoneFunding StatementThis work was supported by the "Peak Project" Scientific Research Special Funding [DFJH2020019], Guangdong Science and Technology Project [2020A111128016] and Guangdong Medical Research Fund Project [A2020006].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consents were obtained from all participants before the study, and the study was approved by the ethics committee of each participating institution. The analysis was conducted on samples collected during standard COVID-19 tests, with no extra burden on patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe supplemental file can be found at the medRxiv website.